Российский паразитологический журнал (Oct 2019)
Subchronic toxicity of the supramolecular complex of triclabendazole
Abstract
Objective of research: Preclinical assessment of subchronic toxicity of the supramolecular complex of Triclabendazole applied on laboratory animals. Materials and methods: Investigations were conducted on 40 male rats with the body mass of 200-220 g. Animals were divided into 4 equal groups. The drug was given to rats of 1, 2 and 3 groups at the doses of 1/5 (2600 mg/kg), 1/10 (1300 mg/ kg) and 1/20 (650 mg/kg) of LD50 (13000 mg/kg), respectively, during 7 days daily orally into the stomach using the gastric tube. Animas from the 4th group received starch paste 1% and served as controls. During the experiment, we observed the general condition of animals, visible physiological functions (food and water intake, etc.), possible signs of intoxication; animals were weighted on the 1st, 3rd, 5th and 7th day of the experiment. On the 8th day of the experiment, animals were killed by decapitation. After killing rats and blood taking, laparotomy was conducted, mass of the main organs (heart, lungs, liver, spleen, brain, seminal glands, thymus, pancreas, and adrenal glands) was determined, their mass coefficients calculated, visible changes detected. Hematological and biochemical indices of rats from experimental and control groups were investigated using the automatic analyzer. Results and discussion: When using the drug in three test doses, general condition and behavior of animals were normal; no signs of intoxication were detected. Triclafascid did not induce an increase in body mass. The investigation of internal organs of experimental animals did not reveal abnormalities. Mass coefficients of internal organs of rats from experimental and control groups did not significantly differ from each other. The application of the drug at the doses of 1/5 and 1/10 of LD50 caused minor decrease in the hemoglobin level related to the controls. The number of erythrocytes, thrombocytes, leucocytes, erythrocyte sedimentation rate (ESR) showed no significant changes. In tested doses, Triclafascid had no significant effect on concentrations of total protein and glucose. Kidney function was estimated by urea and creatinine levels. Both values were equal to the controls. Activities of aspartate and alanine aminotransferase did not show any significant changes after application of the drug in the tested doses, which indicated the normal liver function.
